Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 4/2012

01-08-2012 | SHORT REPORT

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma

Authors: Hee Kyung Ahn, Soohyeon Lee, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Ho Yeong Lim

Published in: Investigational New Drugs | Issue 4/2012

Login to get access

Excerpt

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer-related death [1]. More than 75% of cases occur in the Asian-Pacific region, largely in association with chronic hepatitis B virus (HBV) infection, and 360,000 patients in Eastern Asia die from this disease each year [1]. Diagnosed at early stages, it is potentially curable by surgery and by locoregional procedures. However, disease that is diagnosed at an advanced stage or continues to progress after locoregional therapy has a dismal prognosis because of underlying liver cirrhosis and lack of effective alternative treatments. …
Literature
1.
El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557–2576CrossRefPubMed
2.
Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34CrossRefPubMed
3.
Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390CrossRefPubMed
4.
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109CrossRefPubMed
5.
Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734–745CrossRefPubMed
6.
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338CrossRefPubMed
7.
Dudek AZ, Zolnierek J, Dham A et al (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61–67CrossRefPubMed
8.
Eichelberg C, Heuer R, Chun FK et al (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54:1373–1378CrossRefPubMed
9.
Escudier B, Goupil MG, Massard C, Fizazi K (2009) Sequential therapy in renal cell carcinoma. Cancer 115:2321–2326CrossRefPubMed
10.
Hiles JJ, Kolesar JM (2008) Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65:123–131CrossRefPubMed
11.
Merseburger AS, Simon A, Waalkes S, Kuczyk MA (2009) Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer. Expert Rev Anticancer Ther 9:1429–1434CrossRefPubMed
12.
Richards TM, Plowman PN, Reznek R, Ball SA (2009) A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 21:633–634CrossRef
13.
Zimmermann K, Schmittel A, Steiner U et al (2009) Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76:350–354CrossRefPubMed
14.
Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20–S37CrossRefPubMed
15.
Zhu AX, Duda DG, Sahani DV, Jain RK (2009) Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies. Cancer J 15:263–268CrossRefPubMed
16.
Faivre S, Raymond E, Boucher E et al (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794–800CrossRefPubMed
17.
Huitzil-Melendez FD, Capanu M, O’Reilly EM et al (2010) Advanced hepatocellular carcinoma: which staging systems best predict prognosis? J Clin Oncol 28:2889–2895CrossRefPubMed
Metadata
Title
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma
Authors
Hee Kyung Ahn
Soohyeon Lee
Jong-Mu Sun
Jeeyun Lee
Se Hoon Park
Joon Oh Park
Young Suk Park
Won Ki Kang
Ho Yeong Lim
Publication date
01-08-2012
Publisher
Springer US
Published in
Investigational New Drugs / Issue 4/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-011-9707-4

Other articles of this Issue 4/2012

Investigational New Drugs 4/2012 Go to the issue

PHASE II STUDIES

Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer

PRECLINICAL STUDIES

The role of CXCR2 chemokine receptors in the oral squamous cell carcinoma

SHORT REPORT

Synthesis and cytotoxic activities of some 2-Arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines

SHORT REPORT

Cytotoxicity of the new antimetabolite-bisphosphonate (5-FdU-alendronate) in comparison to standard therapeutics on breast and ovarian cancer cell lines in the ATP tumor chemosensitivity assay

PHASE II STUDIES

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

PHASE I STUDIES

Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits